Skip to content
Brendan J. Guercio, M.D.

Brendan J. Guercio, M.D.

Cancer

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Locations

About Me

Dr. Guercio strives to provide compassionate, personalized, and evidence-based care to all his patients based on shared decision-making with the patient and their family. His decision to specialize in the care of patients with cancer was motivated by experiences caring for his own family members dia...
Dr. Guercio strives to provide compassionate, personalized, and evidence-based care to all his patients based on shared decision-making with the patient and their family. His decision to specialize in the care of patients with cancer was motivated by experiences caring for his own family members diagnosed with cancer.

His areas of expertise include the use of cutting-edge immunotherapy, chemotherapy, and hormone therapy in the treatment of genitourinary cancers, with a focus on the development of new forms of therapy through clinical trials. Dr. Guercio has authored research articles in multiple journals including the Journal of Clinical Oncology. He has received Young Investigator Awards from the Bladder Cancer Advocacy Network (BCAN) and ASCO Conquer Cancer Foundation and has been a recipient of research support from the NIH/NCI.

Dr. Guercio previously served as an Instructor of Medicine at Harvard Medical School and as a Visiting Investigator at Memorial Sloan Kettering Cancer Center.

Certified Specialties

Internal Medicine - American Board of Internal Medicine

Medical Oncology - American Board of Internal Medicine

Faculty Appointments

Assistant Professor - Department of Medicine, Hematology/Oncology (SMD)

Credentials

Residency & Fellowship

Fellowship, Hematology & Oncology, Memorial Sloan-Kettering Cancer Center. 2019 - 2022

Residency, Internal Medicine, Brigham & Womens Hospital. 2017 - 2018

Internship, Internal Medicine, Brigham & Womens Hospital. 2015 - 2016

Education

MD | Harvard Medical School. 2015

Research

Clinical Trials

A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination With Gemcitabine in Adult Subjects With Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status

Lead Researcher: Brendan J Guercio

This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelia...

A Phase 2 Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)

Lead Researcher: Brendan J Guercio

This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline cisplatin-based therapy....